ALVAC-HIV / National Institute of Allergy and Infectious Diseases, Sanofi 
Welcome,         Profile    Billing    Logout  
 15 Diseases   1 Trial   1 Trial   19 News 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ALVAC-HIV / National Institute of Allergy and Infectious Diseases, Sanofi
2004-001525-21: Estudio clínico controlado con placebo, aleatorizado, de fase II, para evaluar la inmunogenicidad y la toxicidad de dos patrones de inducción-refuerzo complementarios con el ALVAC-VIH vCP1452 en pacientes con infección crónica del VIH

Ongoing
2
20
Europe
ALVAC(2)HIV (vCP1452), ALVAC(2)120(B,MN)GNP (vCP1452),
ORVACS, Objectif Recherche Vaccin SIDA
Infección por el VIH
 
 
NCT01435135: Study of Late Boost Strategies for HIV-uninfected Participants From Protocol RV 144

Active, not recruiting
2
162
RoW
ALVAC-HIV, (vCP1521), AIDSVAX B/E, ALVAC-HIV Placebo, AIDSVAX B/E Placebo
U.S. Army Medical Research and Development Command, National Institutes of Health (NIH)
HIV Infections
07/21
07/21
NCT01931358: Study of Boosting Strategies After Vaccination With ALVAC-HIV and AIDSVAX® B/E

Active, not recruiting
2
360
RoW
ALVAC-HIV, AIDSVAX B/E, ALVAC-HIV Placebo, AIDSVAX B/E Placebo
U.S. Army Medical Research and Development Command, National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
12/21
12/21

Download Options